Amgen’s new data for giant cell tumours set for delegates

New oncology data from Amgen’s investigational and approved cancer therapies supports theories that the Rankl pathway plays a mechanistic role in bone loss related to cancer.

Its research into Denosumab, which targets Rankl, or Rank Ligand, is being hailed by the firm as a symbol of its novel drug discovery and development.

Evidence will be presented to delegates at the American Society of Clinical Oncology’s annual meeting.

Roger M Perlmutter, Amgen executive vice-president of research and development (R&D), added: “Amgen initiated a suite of exploratory phase II programs across more than 15 tumor types with eight targeted therapeutics.

“New data from some of these programs will also be presented.”

The company’s presentation will look at the effects of denosumab of giant cell tumours of the bone.

Last year the company opened its largest R&D facility, outside of the US, in Uxbridge, London.

The European Development Centre was located in London because of the UK’s “excellent reputation” for clinical research, according to senior vice president and international chief medical officer, Willard Dere.